@article{Ogbogu:2026:10.1038/s41591-026-04315-8,
author = {Ogbogu, PU and Roufosse, F and Akuthota, P and Kuna, P and Groh, M and Reiter, A and Yokota, A and Siddiqui, SH and Mutsaers, PGNJ and Li, B and Khoury, P and Bahadori, LM and Bednarczyk, A and Bouma, G and Brooks, LG and Ferreira, J and Grindebacke, H and Ho, CN and Jain, P and Palmer, RL and Jison, ML and Klion, AD and NATRON, study group},
doi = {10.1038/s41591-026-04315-8},
journal = {Nat Med},
title = {Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.},
url = {http://dx.doi.org/10.1038/s41591-026-04315-8},
year = {2026}
}

Download

TY  - JOUR
AB  - Benralizumab, an eosinophil-depleting anti-IL-5 receptor α antibody, has demonstrated efficacy in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis and shown promising results in hypereosinophilic syndrome (HES). NATRON was a randomized, double-blind placebo-controlled phase 3 study evaluating the efficacy and safety of benralizumab in FIP1L1::PDGFRA-negative HES. The primary endpoint was time to first HES flare. In total, 133 patients (median (range) age 51 (14-87) years, 62% female) were randomized (1:1) to receive benralizumab 30 mg every 4 weeks or placebo for 24 weeks, in addition to background therapy. Benralizumab significantly reduced the risk of first flare versus placebo (hazard ratio 0.35, 95% CI 0.18 to 0.69, P = 0.0024). Adverse events occurred in 64.2% and 66.7% of benralizumab- and placebo-treated patients, respectively. Benralizumab's safety was consistent with its known profile. These results demonstrate the efficacy and safety of add-on benralizumab in the treatment of HES. ClinicalTrials.gov identifier: NCT04191304 .
AU  - Ogbogu,PU
AU  - Roufosse,F
AU  - Akuthota,P
AU  - Kuna,P
AU  - Groh,M
AU  - Reiter,A
AU  - Yokota,A
AU  - Siddiqui,SH
AU  - Mutsaers,PGNJ
AU  - Li,B
AU  - Khoury,P
AU  - Bahadori,LM
AU  - Bednarczyk,A
AU  - Bouma,G
AU  - Brooks,LG
AU  - Ferreira,J
AU  - Grindebacke,H
AU  - Ho,CN
AU  - Jain,P
AU  - Palmer,RL
AU  - Jison,ML
AU  - Klion,AD
AU  - NATRON,study group
DO  - 10.1038/s41591-026-04315-8
PY  - 2026///
TI  - Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.
T2  - Nat Med
UR  - http://dx.doi.org/10.1038/s41591-026-04315-8
UR  - https://www.ncbi.nlm.nih.gov/pubmed/41917160
ER  - 

Download